Pacific Biosciences of California  

(Public, NASDAQ:PACB)   Watch this stock  
Find more results for PACB
4.70
-0.05 (-0.95%)
Jul 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.67 - 4.95
52 week 2.54 - 8.20
Open 4.77
Vol / Avg. 0.00/702,478.00
Mkt cap 331.57M
P/E     -
Div/yield     -
EPS -1.12
Shares 70.63M
Beta 2.60
Inst. own 66%
Oct 20, 2014
Q3 2014 Pacific Biosciences of California Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 24, 2014
Q2 2014 Pacific Biosciences of California Inc Earnings Call
Jul 24, 2014
Q2 2014 Pacific Biosciences Of California Inc Earnings Release
May 22, 2014
Pacific Biosciences Of California Inc Annual Meeting of Stockholders
May 13, 2014
Pacific Biosciences Of California Inc at Bank of America Merrill Lynch Health Care Conference
Apr 30, 2014
Q1 2014 Pacific Biosciences Of California Inc Earnings Conference Call
Apr 30, 2014
Q1 2014 Pacific Biosciences Of California Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -167.49% -281.37%
Operating margin -160.19% -275.16%
EBITD margin - -255.12%
Return on average assets -57.01% -59.65%
Return on average equity -114.10% -88.81%
Employees 318 -
CDP Score - -

Address

1380 Willow Rd.
MENLO PARK, CA 94025
United States - Map
+1-650-5218000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Pacific Biosciences, Inc. develops Deoxyribonucleic Acid (DNA) sequencing platform. The Company designs and develops a method for single-molecule DNA sequencing that was developed through collaboration between the research groups of Harold Craighead and Watt Webb at Cornell University, United States. The Company's single molecule real time (SMRT) technology's combination of performance characteristics is the result of an approach that uses a single DNA polymerase working in a continuous processing manner to synthesize DNA.

Officers and directors

Michael W. Hunkapiller Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
Susan K. Barnes Chief Financial Officer, Executive Vice President
Age: 60
Bio & Compensation  - Reuters
Kevin P. Corcoran Senior Vice President - Market Development
Age: 55
Bio & Compensation  - Reuters
Michael Phillips Senior Vice President - Research and Development
Age: 63
Bio & Compensation  - Reuters
William Ericson Lead Independent Director
Age: 55
Bio & Compensation  - Reuters
David Botstein Ph.D. Independent Director
Age: 71
Bio & Compensation  - Reuters
Brook H. Byers Ph.D Independent Director
Age: 68
Bio & Compensation  - Reuters
Randy Livingston Independent Director
Age: 60
Bio & Compensation  - Reuters
John F. Milligan Ph.D. Independent Director
Age: 53
Bio & Compensation  - Reuters